Eiger BioPharmaceuticals stock (US28249U1051): asset sale to Amylyx puts focus on strategy and cash runway

Eiger BioPharmaceuticals has sold the GLP?1 receptor antagonist avexitide to Amylyx Pharmaceuticals in a deal valued at about $35 million, shifting its pipeline mix and liquidity profile as the rare-disease company works through restructuring and asset-prioritization steps.

Eiger BioPharmaceuticals has agreed to sell the investigational drug avexitide to Amylyx Pharmaceuticals in a transaction valued at approximately $35.1 million, according to an announcement referenced in recent market news summaries dated 05/10/2026 that cited company disclosures and deal terms from both biopharma groups, highlighting a shift in Eiger’s pipeline focus and its efforts to raise non-dilutive capital to support operations.

Deal summaries indicate that avexitide, a glucagon-like peptide?1 (GLP?1) receptor antagonist being readied for Phase 3 development in rare metabolic conditions, will transfer to Amylyx for an upfront cash component and additional payments tied to future milestones, according to coverage compiled from company communications and financial news reports as of 05/10/2026 from sources such as Nasdaq’s news service and related press-distribution channels.

As of: 05/14/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Eiger BioPharmaceuticals
• Sector/industry: Biotechnology, rare diseases
• Headquarters/country: United States
• Core markets: Rare and ultra-rare disease treatments
• Key revenue drivers: Commercial and pipeline therapies for rare conditions
• Home exchange/listing venue: Nasdaq (ticker: EIGR)
• Trading currency: USD

Eiger BioPharmaceuticals: core business model

Eiger BioPharmaceuticals is a US biotech company focused on therapies for rare and ultra-rare diseases, developing and commercializing treatments that target defined patient populations with high unmet medical need, according to the company’s corporate profile and pipeline overview published on its website and investor materials as of 03/2026.

The company’s strategy centers on repurposing and advancing molecules with established mechanisms or clinical data into indications such as metabolic and infectious rare disorders, an approach that can sometimes shorten development timelines compared with entirely novel compounds, based on descriptions in Eiger’s corporate presentations and prior annual filings released in 2023 and 2024.

Eiger generates revenue primarily from its approved and out-licensed products in specific rare disease segments while investing in clinical-stage candidates that, if successful, could expand its addressable market, according to figures discussed in its Form 10?K for the year ended 12/31/2024, which was filed with the SEC and summarized for investors in early 03/2025.

Main revenue and product drivers for Eiger BioPharmaceuticals

In recent years Eiger’s revenue base has been shaped by a limited number of commercialized or partnered therapies in niche indications, alongside collaboration income and potential milestone payments from development and licensing agreements, according to its 2024 Form 10?K and 2025 first-quarter filings with the SEC, which outline product sales contributions and royalty structures alongside R&D and SG&A expenses.

The company’s pipeline includes clinical candidates aimed at rare metabolic, endocrine, and infectious diseases, where treatment options are often scarce and pricing levels can be higher than in mass-market indications, a dynamic described in Eiger’s corporate deck presented to investors in 11/2024 together with commentary on market sizes, orphan-drug incentives, and regulatory pathways in the United States and Europe.

Within this context the divestiture of avexitide to Amylyx adjusts Eiger’s future revenue mix by removing a late-stage metabolic asset but potentially bringing in upfront cash and contingent payments, which can be deployed toward other programs or to support restructuring efforts, according to deal commentary in biotech trade media and references to Eiger’s capital-allocation priorities in investor communications as of 05/2026.

Why Eiger BioPharmaceuticals matters for US investors

Eiger’s shares trade on Nasdaq under the symbol EIGR, giving US investors direct exposure to a small-cap biotech name focused on rare diseases, a segment that can exhibit binary outcomes around clinical and regulatory milestones but can also benefit from orphan-drug exclusivity and premium pricing, as highlighted in sector analyses from major investment banks and healthcare research boutiques published across 2024.

The US market is a key geography for Eiger both for clinical development and for potential commercialization, given the presence of specialized treatment centers, established reimbursement channels for orphan therapies, and the regulatory framework of the Food and Drug Administration, features that are frequently discussed in the company’s filings and presentations as factors supporting its strategic emphasis on US-based trials and launch planning.

For diversified US investors, Eiger represents a niche position within healthcare and biotechnology that may behave differently from large diversified pharma stocks, with performance often linked to discrete news events such as data readouts, licensing deals like the avexitide sale, and financing transactions, according to historical trading patterns visible in Nasdaq price charts and commentary from healthcare-focused financial media throughout 2023 and 2024.

Conclusion

The sale of avexitide to Amylyx Pharmaceuticals marks a notable portfolio adjustment for Eiger BioPharmaceuticals, providing non-dilutive funding while narrowing its direct exposure to a late-stage GLP?1-related asset. For US investors, the transaction underscores the company’s ongoing restructuring and capital-prioritization efforts as it concentrates resources on selected rare-disease programs. Future performance is likely to depend on the execution of this refocused strategy, the outcome of remaining pipeline catalysts, and the company’s ability to manage its balance sheet in a volatile small-cap biotech environment.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.